Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was granted a Family 4 patent by the Japan Patent Office for its anti-infectives, with expiry in 2041.
“We are encouraged by the Japan Patent Office’s formal recognition of Recce’s new class of anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals. “Global patent protection underscores our commitment to addressing critical unmet medical needs with innovative therapies. We are well-positioned to deliver meaningful solutions for patients worldwide.”
The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), including:
- Process for preparation of RECCE® anti-infectives
- Use of R327/R529 for the treatment of disease, particularly the treatment of bacterial infections, viral infections, and more
- Specifically, further validating RECCE® anti-infectives from studies in acute bacterial skin and skin structure infections (ABSSSI), diabetic foot infections (DFI), burn wounds, lung infections (i.e., ventilator-associated pneumonia/hospital-acquired pneumonia), urinary tract infections, gonorrhoea, influenza, and SARS-CoV2
- Administration by oral, inhalation, transdermal delivery, or by injection (into the bloodstream, intramuscular, and/or intravenous)
- Administration may also be applied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery)
This is the fourth Family 4 patent, alongside Australia, Canada, and Israel, with further Patent Cooperation Treaty Country (PCT) submissions in respective stages of review/allowed.
Japan is the third largest pharmaceutical market in the world,1 with a share of approximately 5% of the global pharmaceutical market.2 The antibiotic resistance market in Japan is expected to reach a projected revenue of $411.3 million by 2030. The Japanese antibiotic resistance market expects a compound annual growth rate of 6.1% from 2024 to 2030.3
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
Media & Investor Relations (AU)
Andrew Geddes
CityPR
+61 (02) 9267 4511
Media (USA)
Michael Fitzhugh
LifeSci Communications
Investor Relations (USA & EU)
Guillaume van Renterghem
LifeSci Advisors
1
2
3
